Gerhild Wildner

ORCID: 0000-0002-2245-7242
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ocular Diseases and Behçet’s Syndrome
  • Systemic Lupus Erythematosus Research
  • Cytomegalovirus and herpesvirus research
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • Immunodeficiency and Autoimmune Disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Retinal Diseases and Treatments
  • Retinal and Optic Conditions
  • Hepatitis B Virus Studies
  • interferon and immune responses
  • Otitis Media and Relapsing Polychondritis
  • Ocular Surface and Contact Lens
  • Vasculitis and related conditions
  • Ocular Infections and Treatments
  • Complement system in diseases
  • Retinal Development and Disorders
  • Chronic Lymphocytic Leukemia Research
  • Inflammasome and immune disorders
  • Ocular Oncology and Treatments
  • Viral gastroenteritis research and epidemiology
  • Autoimmune and Inflammatory Disorders Research
  • Mycobacterium research and diagnosis
  • Adenosine and Purinergic Signaling
  • Chemokine receptors and signaling

Ludwig-Maximilians-Universität München
2016-2025

LMU Klinikum
2016-2025

Ophthalmology Clinic
2010-2017

München Klinik
2000-2017

Universidad Complutense de Madrid
2009

Trinity College Dublin
2009

Max Planck Institute of Neurobiology
2002-2003

STZ eyetrial
1997-2000

He Eye Hospital
1994

Leibniz Institute of Virology (LIV)
1993

Abstract Statistical correlations between the expression of various HLA antigens and certain autoimmune diseases have been observed for both class I II antigens. Autoimmune like spondyloarthropathies anterior uveitis are associated with HLA‐B27, but in Behçet's disease HLA‐B51. We describe a peptide from disease‐associated sharing sequence homologies highly uveitogenic epitope retinal autoantigen S‐antigen. S‐antigen induces animal model is major human disease. The induced Lewis rat and,...

10.1002/eji.1830241103 article EN European Journal of Immunology 1994-11-01

Engineering of adeno-associated virus (AAV) capsids allowed for the development gene therapy vectors with improved tropism and enhanced transduction efficiency. Capsid engineering can also be used to adapt AAV technology applications outside therapy. Here, we investigated modified as scaffolds presentation large immunogenic antigens elicit a strong specific immune response against pathogens. Using SARS-CoV-2 model pathogen, introduced ∼200 amino acids receptor-binding domain (RBD) into...

10.1016/j.omtm.2025.101418 article EN cc-by Molecular Therapy — Methods & Clinical Development 2025-01-22

Equine recurrent uveitis (ERU) is an inflammatory eye disease with high similarity to in man. It the only spontaneous animal model for and most frequent horses affecting up 10% of population. To further investigate pathophysiology ERU we now report establishment inducible horses. An ERU-like was elicited seven out by injection interphotoreceptor retinoid-binding protein (IRBP) complete Freund's adjuvant. Control did not develop uveitis. The characterized a highly reproducible course episodes...

10.1002/1521-4141(200209)32:9<2598::aid-immu2598>3.0.co;2-# article EN European Journal of Immunology 2002-08-28

Equine recurrent uveitis (ERU) is an inflammatory eye disease with high similarity to in man. It the only spontaneous animal model for and most frequent horses affecting up 10% of population. To further investigate pathophysiology ERU we now report establishment inducible horses. An ERU-like was elicited seven out by injection interphotoreceptor retinoid-binding protein (IRBP) complete Freund's adjuvant. Control did not develop uveitis. The characterized a highly reproducible course episodes...

10.1002/1521-4141(200209)32:9<2598::aid-immu2598>3.0.co;2- article EN European Journal of Immunology 2002-09-01

10.1016/j.imbio.2018.09.002 article EN Immunobiology 2018-10-12

Abstract We investigated the role of γ/δ TCR + T cells in induction and suppression cell‐mediated disease experimental autoimmune uveitis. Disease was studied Lewis rats perinatally depleted α/β or subpopulations. Depletion α/δ completely abrogated disease, whereas treatment with anti‐γ/δ antibodies had no influence on onset intensity However, adoptively transferred from orally tolerized could mediate uveitis an antigen‐specific fashion. Uveitis induced by a peptide derived uveitogenic...

10.1002/eji.1830260927 article EN European Journal of Immunology 1996-09-01

The biology of chemokines and their receptors have been linked to the development chronic allograft damage. Effects CCR1 antagonist BX 471 were studied in a Fischer Lewis renal transplantation model at days 10, 21 42 after transplantation. treatment did not effectively reduce signs acute rejection day 10 but significantly improved function morphology posttransplantation. When therapy was initiated on transplantation, glomerulosclerosis tubulointerstitial fibrosis inhibited by Parallel...

10.1111/j.1600-6143.2006.01654.x article EN cc-by-nc-nd American Journal of Transplantation 2007-01-04

A major limitation of most animal models autoimmune diseases is that they do not reproduce the chronic or relapsing-remitting pattern characteristic many human diseases. This problem has been overcome in our rat experimentally induced monophasic uveitis (EAU), which depend on inducing antigen peptides from retinal S-Antigen (monophasic EAU) interphotoreceptor retinoid-binding protein (relapsing EAU). These enable us to compare autoreactive and regulatory T cell populations. Intraocular, but...

10.1371/journal.pone.0049008 article EN cc-by PLoS ONE 2012-11-14

Purpose: The retinal pigment epithelium (RPE) is a main target for complement activation in age-related macular degeneration. anaphylatoxins C3a and C5a, have been thought to mostly play role as chemoattractants macrophages immune cells; here we explore whether they trigger RPE alterations. Specifically, investigated the potential immunoregulatory gate, allowing active changes microenvironment response complement. Design: vitro vivo analysis of signaling pathways. Methods: Individual...

10.3389/fimmu.2017.00703 article EN cc-by Frontiers in Immunology 2017-06-15
Coming Soon ...